MAIA Biotechnology (MAIA) Income from Continuing Operations (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Income from Continuing Operations of 7278929.0 for Q1 2026, down 30.46% year-over-year from 10467263.77 in Q1 2025, and up 73.24% quarter-over-quarter from 27200833.0 in Q4 2025.
MAIA Biotechnology (MAIA) Income from Continuing Operations (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Income from Continuing Operations for 6 consecutive years, with 7278929.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 30.46% year-over-year to 7278929.0; the TTM figure through Mar 2026 stood at 49806914.0 (down 34.77% YoY), while the FY2025 annual figure was 47153247.0, down 48.15% from the prior year.
- Income from Continuing Operations rose to 7278929.0 in Q1 2026 per MAIA's latest filing, from 27200833.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3443086.0 in Q1 2022 and bottomed at 27200833.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 9913983.35 across 5 years, with a median of 7082531.0 in 2023.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations jumped 67.31% — and 2025, when it sank 452.32%.
- MAIA Biotechnology's Income from Continuing Operations stood at 4199539.0 in 2022, then plunged by 51.14% to 6347120.0 in 2023, then grew by 22.41% to 4924792.0 in 2024, then tumbled by 452.32% to 27200833.0 in 2025, then soared by 73.24% to 7278929.0 in 2026.
- Business Quant data shows MAIA's Income from Continuing Operations at 7278929.0 in Q1 2026, 27200833.0 in Q4 2025, and 9613171.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | -8.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.83 Mn |
| Mar 31, 2026 | -7.28 Mn |
| Dec 31, 2025 | -27.20 Mn |
| Sep 30, 2025 | -9.61 Mn |
| Jun 30, 2025 | -5.71 Mn |
| Mar 31, 2025 | -5.58 Mn |
| Dec 31, 2024 | -4.92 Mn |
| Sep 30, 2024 | -11.12 Mn |
| Jun 30, 2024 | -15.33 Mn |
| Mar 31, 2024 | -6.49 Mn |
| Dec 31, 2023 | -6.35 Mn |
| Sep 30, 2023 | -7.08 Mn |
| Jun 30, 2023 | -6.77 Mn |
| Mar 31, 2023 | -13.09 Mn |
| Dec 31, 2022 | -4.20 Mn |
| Sep 30, 2022 | -13.63 Mn |
| Jun 30, 2022 | -20.71 Mn |
| Mar 31, 2022 | -3.44 Mn |
| Dec 31, 2021 | -3.00 Mn |
| Sep 30, 2021 | -2.68 Mn |